Table Info

Table 1.

Revisions to the American Diabetes Association (ADA) 2024 guidelines

Section	Key revisions (2024)
Diagnosis	Glycated hemoglobin (HbA1c) resides at the top of the testing hierarchy as opposed to the earlier recommendations where fasting plasma glucose (FPG) was pre-eminent. HbA1c should not be used for screening of cystic-fibrosis-related diabetes and post-transplantation diabetes [oral glucose tolerance test (OGTT) is preferred].
Classification	Consideration of standardized islet autoantibody tests in adults who phenotypically overlap with type 1 diabetes. Possible association between coronavirus disease 2019 (COVID-19) infection and new-onset type 1 diabetes highlighted.
Associated comorbidities	Recommend screening for heart failure using natriuretic peptides.
Obesity and weight management	Additional anthropometric measurements are to be considered in obese patients. The importance of pharmacotherapy for obesity management highlighted.
Diabetes technology	Emphasized the benefits of using continuous glucose monitoring (CGM) in the management of non-pregnant and pregnant individuals with diabetes. Guidance provided on CGM metrics and their interpretation.

Declarations

Author contributions

DT: Investigation, Writing—original draft. TCA: Conceptualization, Investigation, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

Prof. Tar Choon Aw is the Editorial Board Member of Exploration of Endocrine and Metabolic Diseases, but he had no involvement in the journal review process of this manuscript. Dipti Tiwari has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

IDF Diabetes Atlas Reports [Internet]. International Diabetes Federation; c2022 [cited 2023 Dec 20]. Available from: https://diabetesatlas.org

Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Curr Diab Rep. 2022;22:95–115. [DOI] [PubMed] [PMC]

American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S20–42. [DOI] [PubMed]

American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S111–25. [DOI] [PubMed] [PMC]

Franceschi R. Precision Medicine in Diabetes, Current Research and Future Perspectives. J Pers Med. 2022;12:1233. [DOI] [PubMed] [PMC]

Evans-Molina C, Oram RA. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023;11:76–7. [DOI] [PubMed]

Cherubini V, Chiarelli F. Autoantibody test for type 1 diabetes in children: are there reasons to implement a screening program in the general population? A statement endorsed by the Italian Society for Paediatric Endocrinology and Diabetes (SIEDP-ISPED) and the Italian Society of Paediatrics (SIP). Ital J Pediatr. 2023;49:87. [DOI] [PubMed] [PMC]

Burahmah J, Zheng D, Leslie RD. Adult-onset type 1 diabetes: A changing perspective. Eur J Intern Med. 2022;104:7–12. [DOI] [PubMed]

Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734. [DOI] [PubMed]

10.

Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1:226–37. [DOI] [PubMed] [PMC]

11.

Shivaswamy V, Boerner B, Larsen J. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev. 2016;37:37–61. [DOI] [PubMed] [PMC]

12.

Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021;106:237–50. [DOI] [PubMed] [PMC]

13.

Kovács G, Nagy D, Szilberhorn L, Zelei T, Gaál Z, Vellekoop H, et al. Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Per Med. 2023;20:375–85. [DOI] [PubMed]

14.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S179–218. [DOI] [PubMed]

15.

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388:1353–64. [DOI] [PubMed]

16.

Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2023;28:585–96. [DOI] [PubMed] [PMC]

17.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45:3075–90. [DOI] [PubMed] [PMC]

18.

Lerma EV. Diagnosis 101: diabetic kidney disease. Clin Kidney J. 2022;15:1797–9. [DOI] [PubMed] [PMC]

19.

American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47:S219–30. [DOI] [PubMed]

20.

Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019;86:601–7. [DOI] [PubMed]

21.

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al.; American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148:1606–35. [DOI] [PubMed]

22.

American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S145–57. [DOI] [PubMed]

23.

Kinnunen J, Nikkinen H, Keikkala E, Mustaniemi S, Gissler M, Laivuori H, et al. Gestational diabetes is associated with the risk of offspring’s congenital anomalies: a register-based cohort study. BMC Pregnancy Childbirth. 2023;23:708. [DOI] [PubMed] [PMC]

24.

Zhao D, Liu D, Shi W, Shan L, Yue W, Qu P, et al. Association between Maternal Blood Glucose Levels during Pregnancy and Birth Outcomes: A Birth Cohort Study. Int J Environ Res Public Health. 2023;20:2102. [DOI] [PubMed] [PMC]

25.

Yehuda I. Implementation of Preconception Care for Women With Diabetes. Diabetes Spectr. 2016;29:105–14. [DOI] [PubMed] [PMC]

26.

American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S282–94. [DOI] [PubMed]

27.

Lai M, Weng J, Yang J, Gong Y, Fang F, Li N, et al. Effect of continuous glucose monitoring compared with self-monitoring of blood glucose in gestational diabetes patients with HbA1c<6%: a randomized controlled trial. Front Endocrinol (Lausanne). 2023;14:1174239. [DOI] [PubMed] [PMC]

28.

Di Mario C, Genovese S, Lanza GA, Mannucci E, Marenzi G, Sciatti E, et al.; Expert Panel Group. Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus. Cardiovasc Diabetol. 2022;21:164. [DOI] [PubMed] [PMC]

29.

American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47:S126–44. [DOI] [PubMed]

30.

Aleppo G, Chmiel R, Zurn A, Bandoske R, Creamer P, Neubauer N, et al. Integration of Continuous Glucose Monitoring Data into an Electronic Health Record System: Single-Center Implementation. J Diabetes Sci Technol. 2023;19322968231196168. [DOI] [PubMed]